Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Wave Life Sciences Ltd. WVE NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • SG • USD

SharesGrow Score
61/100
3/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$32.50
+339.8%

Wave Life Sciences Ltd. (WVE) is a Biotechnology company in the Healthcare sector, currently trading at $7.39. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Analyst consensus target is WVE = $33 (+339.8% upside).

Valuation: WVE trades at a trailing Price-to-Earnings (P/E) of -6.2 (S&P 500 average ~25).

Financials: revenue is $43M, +980%/yr average growth. Net income is $204M (loss), growing at -38.3%/yr. Net profit margin is -478.3% (negative). Gross margin is 79.3% (+256.5 pp trend).

Balance sheet: total debt is $18M against $526M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 6.47 (strong liquidity). Debt-to-assets is 2.8%. Total assets: $638M.

Analyst outlook: 24 / 25 analysts rate WVE as buy (96%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 62/100 (Partial), Future 100/100 (Pass), Income 10/100 (Fail).

$32.50
▲ 339.78% Upside
Average Price Target
Based on 25 Wall Street analysts offering 12-month price targets for Wave Life Sciences Ltd., the average price target is $32.50, with a high forecast of $50.00, and a low forecast of $26.00.
Highest Price Target
$50.00
Average Price Target
$32.50
Lowest Price Target
$26.00

WVE SharesGrow Score Overview

72/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 62/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — WVE

✓
VALUE Pass
100/100
WVE trades at a trailing Price-to-Earnings (P/E) of -6.2 (S&P 500 average ~25). Forward PEG -2.59 — Peter Lynch undervalued (≤1.0). Trailing PEG 0.1. Analyst consensus target is $33, implying +346.5% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
WVE: +980%/yr revenue is, -38.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet WVE: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 6.47 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
62/100
WVE: Gross margin is 79.3% (+256.5 pp trend), $1B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 62/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 24 / 25 analysts rate WVE as buy (96%). Analyst consensus target is $33 (+346.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
WVE: Net profit margin is -478.3%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.02-21.73
Volume6.22M
Avg Volume (30D)4.11M
Market Cap$1.39B
Beta (1Y)-1.32
Share Statistics
EPS (TTM)-1.21
Shares Outstanding$168.65M
IPO Date2015-11-11
Employees287
CEOPaul Bolno
Financial Highlights & Ratios
Revenue (TTM)$42.73M
Gross Profit$33.88M
EBITDA$-195.53M
Net Income$-204.38M
Operating Income$-215.38M
Total Cash$602.07M
Total Debt$17.77M
Net Debt$-584.3M
Total Assets$638.5M
Price / Earnings (P/E)-6.1
Price / Sales (P/S)32.56
Analyst Forecast
1Y Price Target$31.00
Target High$50.00
Target Low$26.00
Upside+319.5%
Rating ConsensusBuy
Analysts Covering25
Buy 96% Hold 4% Sell 0%
Price Target Summary
Company Info
CountrySG
ExchangeNASDAQ Global Market
CurrencyUSD
ISINSG9999014716

Price Chart

Track all markets on TradingView
WVE
Wave Life Sciences Ltd. ↗  ·  NASDAQ Global Market
Healthcare • Biotechnology
5.02 52WK RANGE 21.73

People Also View

ALNY
ALNY
Alnylam Pharmaceuticals, Inc.
$339.41
+1.92%
 ARWR
ARWR
Arrowhead Pharmaceuticals, Inc.
$66.69
+4.55%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 VECT
VECT
VectivBio Holding AG
$16.87
+0.12%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message